vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and WOLVERINE WORLD WIDE INC (WWW). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $517.5M, roughly 1.4× WOLVERINE WORLD WIDE INC). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 6.1%, a 12.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 25.5%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $145.6M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 14.5%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Wolverine World Wide is a global designer, manufacturer and marketer of branded footwear, apparel and accessories. It owns popular brands including Merrell, Sperry, Saucony and Hush Puppies, serving outdoor, casual, workwear and athletic segments via e-commerce, retail stores and global wholesale networks.
MEDP vs WWW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $517.5M |
| Net Profit | $135.1M | $31.8M |
| Gross Margin | — | 47.3% |
| Operating Margin | 21.6% | 9.7% |
| Net Margin | 19.1% | 6.1% |
| Revenue YoY | 32.0% | 25.5% |
| Net Profit YoY | 15.5% | 162.8% |
| EPS (diluted) | $4.65 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $517.5M | ||
| Q4 25 | $708.5M | — | ||
| Q3 25 | $659.9M | $470.3M | ||
| Q2 25 | $603.3M | $474.2M | ||
| Q1 25 | $558.6M | $412.3M | ||
| Q4 24 | $536.6M | $494.7M | ||
| Q3 24 | $533.3M | $440.2M | ||
| Q2 24 | $528.1M | $425.2M |
| Q1 26 | — | $31.8M | ||
| Q4 25 | $135.1M | — | ||
| Q3 25 | $111.1M | $25.1M | ||
| Q2 25 | $90.3M | $26.8M | ||
| Q1 25 | $114.6M | $12.1M | ||
| Q4 24 | $117.0M | $23.1M | ||
| Q3 24 | $96.4M | $23.2M | ||
| Q2 24 | $88.4M | $13.8M |
| Q1 26 | — | 47.3% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 47.5% | ||
| Q2 25 | — | 47.2% | ||
| Q1 25 | — | 47.2% | ||
| Q4 24 | — | 43.4% | ||
| Q3 24 | — | 45.1% | ||
| Q2 24 | — | 43.1% |
| Q1 26 | — | 9.7% | ||
| Q4 25 | 21.6% | — | ||
| Q3 25 | 21.5% | 8.4% | ||
| Q2 25 | 20.9% | 8.6% | ||
| Q1 25 | 20.3% | 4.8% | ||
| Q4 24 | 23.4% | 7.4% | ||
| Q3 24 | 21.1% | 7.9% | ||
| Q2 24 | 19.9% | 6.8% |
| Q1 26 | — | 6.1% | ||
| Q4 25 | 19.1% | — | ||
| Q3 25 | 16.8% | 5.3% | ||
| Q2 25 | 15.0% | 5.7% | ||
| Q1 25 | 20.5% | 2.9% | ||
| Q4 24 | 21.8% | 4.7% | ||
| Q3 24 | 18.1% | 5.3% | ||
| Q2 24 | 16.7% | 3.2% |
| Q1 26 | — | $0.37 | ||
| Q4 25 | $4.65 | — | ||
| Q3 25 | $3.86 | $0.30 | ||
| Q2 25 | $3.10 | $0.32 | ||
| Q1 25 | $3.67 | $0.15 | ||
| Q4 24 | $3.67 | $0.29 | ||
| Q3 24 | $3.01 | $0.28 | ||
| Q2 24 | $2.75 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | — |
| Total DebtLower is stronger | — | $621.7M |
| Stockholders' EquityBook value | $459.1M | $408.0M |
| Total Assets | $2.0B | $1.7B |
| Debt / EquityLower = less leverage | — | 1.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $497.0M | — | ||
| Q3 25 | $285.4M | — | ||
| Q2 25 | $46.3M | — | ||
| Q1 25 | $441.4M | — | ||
| Q4 24 | $669.4M | — | ||
| Q3 24 | $656.9M | — | ||
| Q2 24 | $510.9M | — |
| Q1 26 | — | $621.7M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $676.4M | ||
| Q2 25 | — | $708.5M | ||
| Q1 25 | — | $710.8M | ||
| Q4 24 | — | $648.0M | ||
| Q3 24 | — | $702.8M | ||
| Q2 24 | — | $814.7M |
| Q1 26 | — | $408.0M | ||
| Q4 25 | $459.1M | — | ||
| Q3 25 | $293.6M | $376.7M | ||
| Q2 25 | $172.4M | $344.0M | ||
| Q1 25 | $593.6M | $310.6M | ||
| Q4 24 | $825.5M | $312.9M | ||
| Q3 24 | $881.4M | $295.2M | ||
| Q2 24 | $763.6M | $262.1M |
| Q1 26 | — | $1.7B | ||
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.8B | $1.7B | ||
| Q2 25 | $1.6B | $1.8B | ||
| Q1 25 | $1.9B | $1.7B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.1B | $1.8B | ||
| Q2 24 | $1.9B | $1.8B |
| Q1 26 | — | 1.52× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 2.06× | ||
| Q1 25 | — | 2.29× | ||
| Q4 24 | — | 2.07× | ||
| Q3 24 | — | 2.38× | ||
| Q2 24 | — | 3.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $146.2M |
| Free Cash FlowOCF − Capex | $188.1M | $145.6M |
| FCF MarginFCF / Revenue | 26.6% | 28.1% |
| Capex IntensityCapex / Revenue | 0.6% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.43× | 4.60× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $125.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $146.2M | ||
| Q4 25 | $192.7M | — | ||
| Q3 25 | $246.2M | $33.0M | ||
| Q2 25 | $148.5M | $44.6M | ||
| Q1 25 | $125.8M | $-83.8M | ||
| Q4 24 | $190.7M | $82.4M | ||
| Q3 24 | $149.1M | $108.2M | ||
| Q2 24 | $116.4M | $26.7M |
| Q1 26 | — | $145.6M | ||
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | $30.1M | ||
| Q2 25 | $142.4M | $41.2M | ||
| Q1 25 | $115.8M | $-91.4M | ||
| Q4 24 | $183.0M | $74.4M | ||
| Q3 24 | $138.5M | $104.1M | ||
| Q2 24 | $103.5M | $23.7M |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | 6.4% | ||
| Q2 25 | 23.6% | 8.7% | ||
| Q1 25 | 20.7% | -22.2% | ||
| Q4 24 | 34.1% | 15.0% | ||
| Q3 24 | 26.0% | 23.6% | ||
| Q2 24 | 19.6% | 5.6% |
| Q1 26 | — | 0.1% | ||
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.6% | 0.6% | ||
| Q2 25 | 1.0% | 0.7% | ||
| Q1 25 | 1.8% | 1.8% | ||
| Q4 24 | 1.4% | 1.6% | ||
| Q3 24 | 2.0% | 0.9% | ||
| Q2 24 | 2.4% | 0.7% |
| Q1 26 | — | 4.60× | ||
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | 1.31× | ||
| Q2 25 | 1.65× | 1.66× | ||
| Q1 25 | 1.10× | -6.93× | ||
| Q4 24 | 1.63× | 3.57× | ||
| Q3 24 | 1.55× | 4.66× | ||
| Q2 24 | 1.32× | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
WWW
| Sales Channel Through Intermediary | $230.2M | 44% |
| Sales Channel Directly To Consumer | $142.6M | 28% |
| Work Group | $134.0M | 26% |
| Other | $10.7M | 2% |
